Xeris Biopharma Holdings, Inc. XERS
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) is an endocrine/women's health drug developer. Its lead program, XP-8121, is in Phase 3 for hypothyroidism. Its next catalyst on record is XP-8121: Initiation of Phase 3 clinical trial (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: XP-8121 — Initiation of Phase 3 clinical trial (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| XP-8121 | hypothyroidism | small molecule | Phase 3 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 endocrine/women's health companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.